Consent and Educational Sensitive Exams on Anesthetized Patients: Experiences of Medical Students Across Canada.

OBJECTIVE: This study investigates experiences of medical students across Canada related to consent for educational sensitive (i.e., pelvic, rectal) exams under anesthesia (EUAs). METHODS: A bilingual online questionnaire was developed and distributed to medical students across Canada. RESULTS: Of 134 respondents, 63% had performed a pelvic EUA, 35% a rectal EUA, and 11% another sensitive EUA during their training. For those who had performed pelvic EUA, 28% were unsure if consent had taken place, 26% reported no specific consent, 20% reported specific consent, and 25% had mixed experiences of consent. For rectal EUAs, 48% reported no specific consent, 37% were unsure if consent had taken place, 13% reported that there had been specific consent, and 2% reported mixed experiences. Most respondents were uncomfortable (36%) or not sure if they were comfortable (32%) with how the consent process was handled for student pelvic EUAs; 31% were comfortable. In open-ended responses, respondents described a variety of experiences related to variability, discomfort, and authority. CONCLUSION: Non-consensual educational sensitive EUAs continue to take place in medical training across Canada, although practices of consent are highly variable. The majority of respondents reported being uncomfortable or unsure if they are comfortable with how consent for educational sensitive EUAs was practiced during their training, and some respondents struggled to express their discomfort given the power dynamics at play.

Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.

The aim of this study was to assess the effect of 48-week entecavir therapy on serum and intrahepatic hepatitis B virus, covalently closed circular DNA (HBV cccDNA) levels in hepatitis B e antigen (HBeAg)-positive patients. A total of 120 patients with HBeAg-positive chronic hepatitis were treated with entecavir for 48 weeks. Serum HBV markers, total HBV DNA, and HBV cccDNA levels were measured at baseline and week 48. Biopsies from 20 patients were available for both intrahepatic total HBV DNA and cccDNA testing at these timepoints. HBV cccDNA levels were decreased from a median level of 5.1×106 copies/mL at baseline to a median level of 2.4×103 copies/mL at week 48. Reduction magnitudes of HBV cccDNA in patients with normalized alanine aminotransferase levels and those undergoing HBeAg seroconversion were significantly greater than those in alanine aminotransferase-abnormal and HBeAg positive patients. Intrahepatic HBV cccDNA was decreased significantly after 48 weeks of treatment, but could not be eradicated. In conclusion, treatment of HBeAg-positive hepatitis B patients with entecavir for 48 weeks decreased serum and intrahepatic HBV cccDNA significantly, and the magnitude of HBV cccDNA reduction was related to total HBV DNA decrease, alanine aminotransferase normalization, and HBeAg seroconversion.

Clinical features of elderly Chinese patients with autoimmune hepatitis.

BACKGROUND/AIMS: To study the clinical features of elderly Chinese patients with autoimmune hepatitis. MATERIALS AND METHODS: The clinical features of 36 patients diagnosed at age >60 years were compared with those of 39 patients aged <50 years. RESULTS: The M:F ratio was 1:35 (>60 years) vs. 3:36 (<50 years). The patients >60 years had a higher frequency of cirrhosis at presentation than the patients <50 years (52.8% vs. 15.4%, p=0.001). The patients >60 years also had a significantly increased incidence of ascites at presentation (41.7% vs. 10.3%, p=0.001) and lower serum albumin levels (p=0.037). There were significant differences between older and younger patients with respect to the frequencies or titers of anti-nuclear antibody (46.2% vs. 83.3%, p=0.011). HLA DR3 positivity occurred more frequently in the patients <50 years than in those >60 years (59.0% vs. 19.4%, p<0.001), whereas HLA DR4 occurred more often in the patients >60 years (63.9% vs. 25.6%, p=0.001). Treatment failure occurred more frequently in the patients <50 years (28.2% vs. 9.1%, p=0.041). However, there were no significant differences between the groups with respect tomode of onset, other clinical signs at presentation biochemical parameters, and smooth muscle antibody positivity. CONCLUSION: Elderly patients have a greater frequency of cirrhosis at presentation, anti-nuclear antibody, HLA DR4 positivity than patients <50 years, and they have a lower occurrence of treatment failure. Conventional corticosteroid regimens may be an effective management for older patients with autoimmune hepatitis.